Abstract：Objective To investigate the efficacy and adverse reactions of nicorandil in the treatment of non-ST elevation acute coronary syndrome.Methods A total of 170 patients with non-ST-elevation acute coronary syndrome were treated with nitroglycerin and nicorandil respectively between October 2017 and January 2019. In addition to routine treatment such as antiplatelet and lipid regulation, 86 patients in the nitroglycerin group were treated with 25 mg nitroglycerin while another 84 patients in the nicorandil group were treated with 12 mg nicorandil. The clinical efficacy and incidence of adverse reactions were compared between the two groups.Results After one week of treatment, the frequency of angina attack and ST segment depression in the nicorandil group were significantly alleviated. The effective rate of treatment was 97.6%. The treatment was markedly effective in 50 cases, effective in 32 cases but ineffective in 2 cases. In the nitroglycerin group, the effective rate was 73.3%, as the treatment was markedly effective in 17 cases, effective in 23 cases and ineffective in 46 cases. The incidence of adverse reactions was 56.0% in the nicorandil group and 86.0% in the nitroglycerin group (P< 0.05). All the patients were followed up for 3 to 6 months. There was no recurrence of angina pectoris in the nicorandil group, but angina pectoris recurred in 30 patients in the nitroglycerin group within 2 to 4 months after treatment, which was improved after readmission.Conclusions NCR has a good clinical effect in the treatment of non-ST elevation acute coronary syndrome with fewer adverse reactions.
Amsterdam E A,Wenger N K,Brindis R G,et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes:executive summary[J].J Am Cardiol,2014,64(24):2645-2687.
[6]
Miura T,Miura T,Miki T.ATP- sensitive K+ channel openers: old drugs with new clinical benefits for the heart[J].Curr Vasc Pharmacol,2003,1(3):251-258.
[7]
Mohler E R,Hiatt W R,Olin J W,et al. Treatment of intermittent claudication with beraprost sodium,an orally active prostaglandin 12 analogue: a double-blinded,randomized,controlled trial[J].J Am Coll Cardiol,2003,41(10):1679-1686.
[8]
Task F M,Montalescot G,Sechtem U,et al.2013 ESC guidelines on the management of stable coronary artery disease of the european society of cardiology[J].Eur Heart J,2013,34(38):2940-3003.
[9]
Tarkin J M, Kaski J C. Vasodilator therapy: nitrates and nicorandil[J].Cardiovasc Drugs Ther,2016,30(4): 367-378.
[10]
Lanza G A,Parrinello R,Figliozzi S. Management of microvascular angina pectoris[J]. Am J Cardiovasc Drugs,2014,14(1): 31-40.
[11]
Kostic J,Djordjevicn D A,Dobric M,et al. The effects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI[J].Cardiovasc Ultrasound, 2015,13: 26.
Nawa T,Nishigaki K,Kinomura Y,et al.Continuous intrave-nous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast in duced nephropathy in patients with poor renal function[J].Int J Cardiol,2015,195(15): 228-234.
2019, Vol. 30 
